Clopidogrel in interventional cardiology: Questions answered and questions remaining

Canadian Journal of Cardiology

Volumn 18, Issue 7, 2002, Pages 739-748

  Nikhil, Janarthan Y ^a   Radhakrishnan, Sam ^a   Paradiso Hardy, Fran L ^a   Cohen, Eric A ^a  

^a NONE   (Canada)

Author keywords

Angioplasty; Drugs; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PACLITAXEL; PLACEBO; THIENOPYRIDINE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ATHEROSCLEROSIS; BLEEDING; BLOOD DYSCRASIA; BLOOD TOXICITY; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GRAFT OCCLUSION; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; IMPLANTATION; LONG TERM CARE; META ANALYSIS; NAUSEA; NEUTROPENIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; POSTOPERATIVE CARE; RESTENOSIS; REVIEW; RISK ASSESSMENT; SUBSTITUTION THERAPY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT PLANNING;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; STENTS; TICLOPIDINE;

EID: 0036332691     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Angiographic follow-up after placement of a self-expanding coronary-artery stent
2. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
3. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
4. Porcine model of stent thrombosis: Platelets are the primary component of acute stent closure
5. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting
6. Changing from intensive anticoagulation to treatment with aspirin alone for coronary stents: The experience of one center in the United Kingdom
7. Antiplatelet effect of ticlopidine after coronary stenting
8. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans
9. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
10. Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA
11. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
12. Clopidogrel inhibition of stent, graft and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
13. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit
14. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty
15. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents
16. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
17. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study
18. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS)
19. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting
20. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation
21. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation: Comparison of aspirin alone versus combined ticlopidine and aspirin therapy
22. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group
23. Adverse cutaneous reactions to ticlopidine in patients with coronary stents
24. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
25. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
26. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
27. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population
28. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflects in primary care settings?
29. Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified?
30. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
31. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting
32. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
33. Hematologic dyscrasia associated with ticlopidine therapy: Evidence for causality
34. Thrombotic thrombocytopenic purpura after stenting and ticlopidine
35. Active pharmacovigilance efforts compared to the FDA's Medwatch drug surveillance program for the detection of ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura
36. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention
37. Safety and efficacy and ticlopidine for only 2 weeks after successful intracoronary stent placement
38. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events
39. Thrombotic thrombocytopenic purpura associated with clopidogrel
40. Thrombotic thrombocytopenic purpura related to ticlopidine
41. CAPRIE Trial
42. Fatal aplastic anemia associated with clopidogrel
43. Use of clopidogrel in coronary stenting: What was the question?
44. Clopidogrel versus ticlopidine after intracoronary stent placement
45. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
46. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents
47. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting
48. A comparison of clopidogrel to ticlopidine therapy for the prevention of major adverse cardiac events at thirty days and six months following coronary stent implantation
49. Short term mortality lower with clopidogrel than ticlopidine following coronary artery stenting
50. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
51. Antithrombotic therapy in patients undergoing percutaneous coronary intervention
52. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
53. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions
54. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin
55. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
56. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
57. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
58. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects
59. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects
60. Single-dose pharmacodynamics of clopidogrel
61. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
62. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: Evidence of inflammatory responses in coronary angioplasty
63. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty
64. A randomized dose comparison of the effects of a high versus conventional loading dose of clopidogrel on platelet aggregation prior to percutaneous coronary intervention
65. What is the appropriate loading dose of clopidogrel prior to stent implantation? Insights from a platelet inhibition study
66. Clopidogrel therapy in patients undergoing coronary stenting: Value of a high loading-dose regimen
67. Risk of post-operative hemorrhage associated with ticlopidine or clopidogrel use prior to coronary artery bypass grafting
68. Clopidogrel for prevention of thrombotic complications after cardiac surgery: A word of caution
69. Impact of preoperative clopidogrel in coronary artery bypass grafting
70. The changing face of coronary interventional practice: The Mayo Clinic experience
71. Reduction in angioplasty complications after the introduction of coronary stents: Results from a consecutive series of 2242 patients
72. Stand-by versus stent-by during percutaneous transluminal coronary angioplasty
73. Intracoronary stenting and risk for major adverse cardiac events during the first month
74. Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus
75. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery
76. Catheter-based radiotherapy to inhibit restenosis after coronary stenting
77. Intracoronary beta radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis
78. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis
79. Neointimal responses 3 months after (32)P beta-emitting stent placement
80. Prolonged antiplatelet therapy and reduced stenting improve the safety of coronary radiation therapy: The SCRIPPS III registry
81. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary beta-radiation in patients with in-stent restenosis
82. Late acute thrombosis after paclitaxel eluting stent implantation
83. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody fab 7E3 in high-risk coronary angioplasty
84. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine
85. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
86. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
87. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
88. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
89. P-selectin induces the expression of tissue factor on monocytes
90. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-α secretion
91. Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease?
92. A single loading dose of clopidogrel reduces platelet activation, monocyte activation and platelet-monocyte interactions in patients undergoing percutaneous coronary intervention
93. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: Data from the evaluation of platelet IIb/IIIa inhibitor for stenting (EPISTENT) trial
94. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
95. Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty